skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

Review

(2190) Views  (956) Full article downloads

Authors: César Bustos, Jose L Del Pozo

Published Date April 2010 Volume 2010:3 Pages 5 - 14
DOI: http://dx.doi.org/10.2147/IDR.S3681

César Bustos1, Jose L Del Pozo1,2

1Division of Infectious Diseases, 2Division of Clinical Microbiology, Clínica Universidad de Navarra, Spain

Abstract: Antimicrobial resistance is a global concern. Over the past few years, considerable efforts and resources have been expended to detect, monitor, and understand at the basic level the many different facets of emerging and increasing resistance. Development of new antimicrobial agents has been matched by the development of new mechanisms of resistance by bacteria. Current antibiotics act at a variety of sites within the target bacteria, including the cross-linking enzymes in the cell wall, various ribosomal enzymes, nucleic acid polymerases, and folate synthesis. Ceftobiprole is a novel parenteral cephalosporin with high affinity for most penicillin-binding proteins, including the mecA product penicillin-binding protein 2a, rendering it active against methicillin-resistant staphylococci. Its in vitro activity against staphylococci and multiresistant pneumococci, combined with its Gram-negative spectrum comparable to that of other extended-spectrum cephalosporins, its stability against a wide range of beta-lactamases, and its pharmacokinetic and safety profiles make ceftobiprole an attractive and well tolerated new antimicrobial agent. The US Food and Drug Administration granted ceftobiprole medocaril fast-track status in 2003 for the treatment of complicated skin infections and skin structure infections due to methicillin-resistant staphylococci, and subsequently extended this to treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia due to suspected or proven methicillin-resistant Staphylococcus aureus.

Keywords: ceftobiprole, methicillin-resistant staphylococci, skin infection, hospital acquired pneumonia








Readers of this article also read:

Current and novel antibiotics against resistant Gram-positive bacteria
The determinants of the antibiotic resistance process
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus
Anidulafungin and its role in candida infections
Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection
Boceprevir in the treatment of chronic hepatitis C virus infection
Differences in maintenance of mean blood glucose (BG) and their association with response to “recognizing hunger”
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University